Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan

Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan

Background/Purpose: There is a lack of data on nivolumab treatment outcomes in Taiwanese patients with advanced or recurrent non-small cell lung cancer (NSCLC) ineligible for radical radiotherapy and resistant to platinum-based chemotherapy. We investigated the safety and efficacy of nivolumab in th...

Full description

Bibliographic Details
Main Authors: Yuh-Min Chen, James Chih-Hsin Yang, Wu-Chou Su, Inn-Wen Chong, Te-Chun Hsia, Meng-Chih Lin, Gee-Chen Chang, Chao-Hua Chiu, Chao-Chi Ho, Shang-Yin Wu, Jen-Yu Hung, Chin-Chou Wang, Tsung-Ying Yang, Chong-Jen Yu
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:Journal of the Formosan Medical Association
Subjects:
Monoclonal antibodies
Non-small cell lung carcinoma
Programmed cell death 1 receptor
Safety
Taiwan
Online Access:http://www.sciencedirect.com/science/article/pii/S0929664620300085

Internet

http://www.sciencedirect.com/science/article/pii/S0929664620300085

Similar Items